Form 4: AN2 Therapeutics COO Sells Shares for Tax Obligations

AN2 Therapeutics' Chief Operating Officer and Chief Legal Officer, Joshua M. Eizen, sold shares of common stock to cover tax withholding obligations from RSU vesting.

Summary

• Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc. (ANTX), reported sales of common stock.
• On January 5, 2026, Eizen sold 17,923 shares at a weighted average price of $1.0014 per share.
• On January 6, 2026, Eizen sold an additional 6,931 shares at a price of $1.012 per share.
• These sales, totaling 24,854 shares, were executed to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• Following these transactions, Eizen beneficially owns 152,499 shares of common stock, which includes various tranches of unvested RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a non-discretionary sale to cover tax obligations from RSU vesting, which is a routine event and does not reflect a change in the executive's confidence in the company or its fundamentals. While it reduces insider ownership, the reason for the sale mitigates any negative interpretation.

Positives

• The transaction was a non-discretionary sale to cover tax obligations, indicating a routine event rather than a signal of lack of confidence in the company.

Negatives

• A reduction in the direct beneficial ownership of common stock by a key executive, Joshua M. Eizen, by 24,854 shares.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine event common across all industries for executives receiving equity compensation in the form of Restricted Stock Units (RSUs). The sale to cover tax obligations upon vesting is a standard practice and does not inherently reflect on the company's industry-specific performance or trends.

Comparison to Industry Standards

• Sales of shares to cover tax withholding obligations upon RSU vesting are a standard practice for executives across publicly traded companies, aligning with typical executive compensation and tax management strategies.
• The volume of shares sold (24,854) is not unusually large for an executive at a public company, especially when compared to the total outstanding shares or typical daily trading volumes, suggesting it is a routine compliance event rather than a significant market signal.

Stakeholder Impact

• Shareholders: A minor reduction in direct beneficial ownership by a key executive, which is generally a neutral event given the reason for the sale (tax obligations) but could be perceived as a slight negative by some investors if not fully understood.
• Employees: No direct impact mentioned.

Next Steps

• Future vesting of 30,000 RSUs annually over four years from January 1, 2024.
• Future vesting of 60,000 RSUs with 25% on January 1, 2025, 50% on January 1, 2026, and 25% on July 1, 2026.
• Future vesting of 31,500 RSUs annually over four years from November 4, 2024.
• Future vesting of 58,500 RSUs annually over four years from January 1, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations associated with RSU vesting. Such transactions are common and typically do not signal a change in the company's fundamental outlook or the executive's long-term confidence. Therefore, based solely on this filing, there is no new information to warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Stock Sale